Our top pick for
Nektar Therapeutics is a biotechnology business based in the US. Nektar Therapeutics shares (NKTR) are listed on the NASDAQ and all prices are listed in US Dollars. Nektar Therapeutics employs 718 staff and has a trailing 12-month revenue of around USD$152.9 million.
|52-week range||USD$13.63 - USD$26.75|
|50-day moving average||USD$20.6055|
|200-day moving average||USD$18.5233|
|Wall St. target price||USD$31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.435|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Nektar Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Nektar Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Nektar Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.22. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Nektar Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$152.9 million|
|Gross profit TTM||USD$133.4 million|
|Return on assets TTM||-13.51%|
|Return on equity TTM||-35.8%|
|Market capitalisation||USD$4.3 billion|
TTM: trailing 12 months
There are currently 21.2 million Nektar Therapeutics shares held short by investors – that's known as Nektar Therapeutics's "short interest". This figure is 7.6% down from 22.9 million last month.
There are a few different ways that this level of interest in shorting Nektar Therapeutics shares can be evaluated.
Nektar Therapeutics's "short interest ratio" (SIR) is the quantity of Nektar Therapeutics shares currently shorted divided by the average quantity of Nektar Therapeutics shares traded daily (recently around 1.6 million). Nektar Therapeutics's SIR currently stands at 13.24. In other words for every 100,000 Nektar Therapeutics shares traded daily on the market, roughly 13240 shares are currently held short.
However Nektar Therapeutics's short interest can also be evaluated against the total number of Nektar Therapeutics shares, or, against the total number of tradable Nektar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nektar Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Nektar Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.2361% of the tradable shares (for every 100,000 tradable Nektar Therapeutics shares, roughly 236 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Nektar Therapeutics.
Find out more about how you can short Nektar Therapeutics stock.
We're not expecting Nektar Therapeutics to pay a dividend over the next 12 months.
Nektar Therapeutics's shares were split on a 2:1 basis on 23 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Nektar Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Nektar Therapeutics shares which in turn could have impacted Nektar Therapeutics's share price.
Over the last 12 months, Nektar Therapeutics's shares have ranged in value from as little as $13.63 up to $26.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nektar Therapeutics's is 1.6286. This would suggest that Nektar Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the company sis developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; SFJ Pharmaceuticals, Inc.; and Biolojic Design, Ltd. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.